Impact of obesity on immune-related adverse events and tyrosine kinase inhibitor side effects in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Alharbi, Malak
Tariq, Muhammad Junaid
Jatwani, Karan
George, Saby
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY USA
[2] Roswell Pk Canc Inst, Buffalo, IL USA
[3] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4560
引用
收藏
页数：1
相关论文
共 50 条
  • [11] C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients
    Kankkunen, Elisa
    Penttila, Patrick
    Peltola, Katriina
    Bono, Petri
    ACTA ONCOLOGICA, 2022, 61 (10) : 1240 - 1247
  • [12] Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC).
    Parikh, Anish B.
    Psutka, Sarah P.
    Yang, Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li, Mingjia
    Mori-Vogt, Sherry
    Hinkley, Megan
    Orcutt, Delaney
    Trott, Elliott
    Gross, Evan
    Hussey, Duncan
    Kramer, Joel
    Oliva, Kaylee
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven K.
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?
    Afshar, Mehran
    Patel, Hiten R. H.
    Jain, Ankit
    Kumar, Abhishek
    Patel, Prashant
    James, Nicholas D.
    Porfiri, Emilio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 529 - 532
  • [14] SALVAGE IMMUNE CHECKPOINT INHIBITOR (IO) PLUS TYROSINE KINASE INHIBITOR (TKI) COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Parikh, Anish
    Psutka, Sarah
    Yang, Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li, Mingjia
    Mori-Vogt, Sherry
    Hinkley, Megan
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven
    Orcutt, Delaney
    Gross, Evan
    Hussey, Duncan
    Trott, Elliot
    Kramer, Joel
    Oliva, Kaylee
    Gore, John
    Schade, George
    Lin, Daniel
    Tykodi, Scott
    Hall, Evan
    Thompson, John
    Yin, Ming
    JOURNAL OF UROLOGY, 2021, 206 : E261 - E261
  • [15] Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center
    McGhie, J.
    Mackenzie, M. J.
    Winquist, E.
    Ernst, S.
    Sax, L.
    O'Brien, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [16] Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
    Leucht, Katharina
    Ali, Nalyan
    Foller, Susan
    Grimm, Marc-Oliver
    CANCERS, 2022, 14 (18)
  • [17] Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma
    Corona-Rodarte, Eduardo
    Olivas-Martinez, Antonio
    Remolina-Bonilla, Yuly A.
    Dominguez-Cherit, Judith G.
    Lam, Elaine T.
    Bourlon, Maria T.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (10) : 1242 - 1247
  • [18] Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
    Sayer, Michael R.
    Mambetsariev, Isa
    Lu, Kun-Han
    Wong, Chi Wah
    Duche, Ashley
    Beuttler, Richard
    Fricke, Jeremy
    Pharoan, Rebecca
    Arvanitis, Leonidas
    Eftekhari, Zahra
    Amini, Arya
    Koczywas, Marianna
    Massarelli, Erminia
    Roosan, Moom Rahman
    Salgia, Ravi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [19] Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
    Kobayashi, Kazuo
    Iikura, Yusuke
    Hiraide, Makoto
    Yokokawa, Takashi
    Aoyama, Takeshi
    Shikibu, Sari
    Hashimoto, Koki
    Suzuki, Kenichi
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    IN VIVO, 2020, 34 (05): : 2647 - 2652
  • [20] Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).
    Desai, Kunal
    Rybicki, Lisa A.
    Nizam, Amanda
    Wood, Laura S.
    Allman, Kimberly D.
    Martin, Allison
    Calabrese, Cassandra
    Gilligan, Timothy D.
    Gupta, Shilpa
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345